Kewalramani Reshma, CEO and President, has demonstrated a clear selling bias in her insider trading activity, as evidenced by SEC Form 4 filings. Over the course of 39 transactions, all involving Vertex Pharmaceuticals (VRTX), Reshma has sold shares totaling approximately $75.76 million, compared to purchases valued at just $4.19 million. This trend has persisted in recent activity, with 13 sales recorded since February 2026, including multiple transactions on February 27, 2026, ranging from $57,780 to $7.72 million. Notably, her largest recent sale occurred on February 27, 2026, valued at $7.72 million, followed by another significant sale of $2.97 million on the same day. Prior to this, Reshma executed several other sizable sales, including $6.36 million on February 13, 2026, and $6.75 million on February 26, 2025. While she has made occasional purchases, such as $2.42 million on February 24, 2026, and $3.17 million on February 17, 2026, these are overshadowed by the volume and value of her sales. Reshma’s trading activity reflects a consistent pattern of divesting her holdings in Vertex Pharmaceuticals, with no transactions reported outside this single company.
AI-assisted summary